SS
SSKN.US STRATA Skin Sciences Inc
- Market cap
- USD 588.00
- P/E
- -
- P/B
- 0.00x
- ROE
- -215.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is SSKN.US undervalued?
Graham numberThe Graham number of STRATA Skin Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STRATA Skin Sciences Inc fundamental analysis
No fundamental analysis for STRATA Skin Sciences Inc yet.
STRATA Skin Sciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STRATA Skin Sciences Inc
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, viti…
Full company profileSTRATA Skin Sciences Inc financial statements
STRATA Skin Sciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 31.8M | 31.4M | 29.9M | 31.6M | 23.1M | 30.0M | 36.2M | 33.4M | 33.6M | 30.7M |
| Gross Profit | 19.1M | 18.0M | 17.1M | 20.3M | 14.1M | 19.9M | 21.8M | 18.5M | 19.1M | 17.9M |
| Operating Income | -3.60M | -2.41M | -3.36M | -3.01M | -4.08M | -4.40M | -4.65M | -8.60M | -9.26M | -5.84M |
| EBITDA | 2.77M | 4.54M | 2.04M | 1.81M | -15.0K | 1.73M | 1.13M | -3.38M | -2.84M | 177K |
| Net Income | -3.34M | -21.5M | -4.03M | -3.79M | -4.41M | -2.71M | -5.55M | -10.8M | -10.1M | -6.26M |
| EPS | -1.44 | -3.26 | -0.13 | -0.12 | -0.13 | -0.08 | -0.16 | -0.31 | -0.26 | -0.13 |
| Balance Sheet | ||||||||||
| Total Assets | 43.2M | 38.6M | 47.5M | 47.3M | 46.8M | 46.6M | 52.3M | 42.0M | 36.2M | 30.5M |
| Total Liabilities | 28.5M | 16.4M | 16.3M | 18.7M | 20.9M | 21.2M | 30.4M | 29.3M | 31.2M | 27.6M |
| Shareholders' Equity | 14.7M | 22.2M | 31.2M | 28.7M | 25.9M | 25.4M | 21.8M | 12.7M | 4.97M | 2.91M |
| Cash & Short-term Investments | 3.93M | 4.07M | 16.5M | 8.13M | 10.6M | 12.6M | 5.43M | 6.78M | 7.26M | 7.91M |
| Total Debt | 23.8M | 10.6M | 7.40M | 8.67M | 10.9M | 8.03M | 8.44M | 15.6M | 16.4M | 16.3M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 322K | 4.14M | 2.90M | 2.23M | 2.10M | 1.51M | -1.11M | -519K | 188K | -2.79M |
| Capital Expenditure | 1.01M | 1.74M | 1.76M | 2.79M | 2.16M | 3.65M | 3.55M | 5.02M | 1.64M | 1.47M |
| Free Cash Flow | -686K | 2.40M | 1.13M | -562K | -63.0K | -2.15M | -4.66M | -5.54M | -1.45M | -4.26M |
| Ratios | ||||||||||
| ROE | -22.7% | -96.7% | -12.9% | -13.2% | -17.0% | -10.6% | -25.4% | -85.4% | -202.9% | -215.3% |
| ROA | -7.7% | -55.7% | -8.5% | -8.0% | -9.4% | -5.8% | -10.6% | -25.8% | -27.9% | -20.5% |
| Net Profit Margin | -10.5% | -68.4% | -13.5% | -12.0% | -19.1% | -9.0% | -15.3% | -32.5% | -30.1% | -20.4% |
| Debt to Equity | 1.62x | 0.48x | 0.24x | 0.30x | 0.42x | 0.32x | 0.39x | 1.23x | 3.31x | 5.59x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
STRATA Skin Sciences Inc dividends
STRATA Skin Sciences Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Jun 7, 2024.
Who owns STRATA Skin Sciences Inc
- Insiders 3.76%
- Institutions 31.59%
- Public & others 64.65%
- Shares outstanding 5.89M
- Free float 4.06M
Top funds holding SSKN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| NT Quality Small Cap Core | 4.00 | 0.00% | 0.00% | Mar 2026 |
Top institutions holding SSKN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Creative Planning Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| 22NW, LP | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Hanson Mcclain Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| BlackRock Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Tower Research Capital LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Financial Perspectives Inc | 0.00 | 0.00% | -100.00% | Mar 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Apollon Wealth Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Renaissance Technologies Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Nantahala Capital Management, LLC | 0.00 | 0.00% | -100.00% | Mar 2026 |
| Bank of America Corp | 0.00 | 0.00% | -100.00% | Mar 2026 |
STRATA Skin Sciences Inc company profile
- Company name
- STRATA Skin Sciences Inc
- Ticker
- SSKN.US
- Exchange
- USA Stocks
- Listed since
- Oct 28, 2005
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 114
- Fiscal year end
- December
- Address
- 5 Walnut Grove Drive, Horsham, PA, United States, 19044
- Phone
- 215 619 3200
- Website
- strataskinsciences.com
About STRATA Skin Sciences Inc
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
STRATA Skin Sciences Inc management
5- Dr. Dolev Rafaeli Ph.D.Vice-Chairman & President · born 1964
- Mr. John GillingsPrincipal Financial Officer & Chief Accounting Officer · born 1976
- Mr. Shmuel GovChief Operating Officer · born 1960
- Ms. Erica JordanDirector & CEO · born 1977
- Mr. Jay SturmGeneral Counsel & Corporate Secretary · born 1956